|Bid||1.10 x 1200|
|Ask||1.20 x 800|
|Day's Range||1.1400 - 1.1944|
|52 Week Range||0.6520 - 3.4900|
|Beta (3Y Monthly)||3.21|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.67|
Jim Cramer and Novartis CEO Vas Narasimhan discuss how the drugmaker is refocusing its business to leverage new-age treatments and potential cures.
Novartis announced today that the US Food and Drug Administration (FDA) has approved Egaten® (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. This makes Egaten the only FDA-approved drug for people with this disease and is expected to facilitate broader access to this important drug not only in the US, but also in affected countries worldwide.
Novan, Inc. ("the Company" or "Novan") (NOVN) today provided an update on several aspects of its business. Novan announces that it has been granted an end-of-Phase 2 meeting with the FDA in early March 2019 for the SB206 molluscum program.
After years and ups and downs while the company has been trying to push out their nitric oxide candidates, Novan now faces a delisting threat due to steadily decreasing stock value.
Paula Brown Stafford promoted to President and newly created role of Chief Operating Officer of Novan Dr. Carri Geer promoted to Senior Vice President and Chief Technology.
Pharmaceutical companies in the Triangle were far from exempt from a worldwide dive in stock prices, with some companies sliding more than 50 percent.
A look at the shareholders of Novan, Inc. (NASDAQ:NOVN) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see Read More...
Novan's (NOVN) nitric oxide candidate, SB206, demonstrates statistically significant reduction of lesions in patients with molluscum contagiosum.
Novan, Inc. ("the Company" or "Novan") (NOVN) today announced full top line results from the Company’s Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum, including results from the fourth cohort, SB206 12% once-daily. Results demonstrated a clear treatment effect on the complete clearance of all molluscum lesions at Week 12 for 12% once-daily SB206 gel, with signs of efficacy evident as early as Week 2.
Novan (NOVN) delivered earnings and revenue surprises of 15.63% and -4.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The number of public companies based in the Triangle has shrunk in recent years as acquisitions have meant a change in headquarters location, or even taking the company private.